m6A-mRNA Methylation Regulates Gene Expression and Programmable m6A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma

Ying Gan,Aolin Li,Jun Liu,Xiaofei Wang,Zhenan Zhang,Qinhan Li,Xiongjun Ye,Lin Yao,Qian Zhang
DOI: https://doi.org/10.3389/fgene.2021.795611
IF: 3.7
2022-01-21
Frontiers in Genetics
Abstract:Background: N 6 -methyladenosine (m 6 A) is the most extensive messenger RNA modification. Despite recent advances in the biological roles of m 6 A, its role in the development and progression of renal cell carcinoma (RCC) remains unclear. Methods: In this study, we gained the transcriptome-wide m 6 A profile and gene expression pattern in RCC and paired adjacent peritumoral tissues by meRIP-seq and RNA-seq. m 6 A modifications of mRNAs were validated by meRIP-qPCR in tissues, and targeted methylation or demethylation was validated by using a CRISPR-Cas13b-based tool in RCC cell lines. Results: Our findings showed that there were 13,805 m 6 A peaks among 5,568 coding gene transcripts (mRNAs) in adjacent tissues and 24,730 m 6 A peaks among 6,866 mRNAs in tumor tissues. Furthermore, m 6 A modification sites were usually located in the coding sequences (CDS), and some near the start and stop codons. Gene Ontology analysis revealed that coding genes had differential N 6 -methyladenosine sites and were enriched in kidney development and cancer-related signaling pathways. We also found that different levels of m 6 A modifications could regulate gene expression. Conclusion: In summary, our results provided evidence for studying the potential function of RNA m 6 A modification and m 6 A-mediated gene expression regulation in human RCC.
genetics & heredity
What problem does this paper attempt to address?